Njar VC - Search Results

1

Synthesis and evaluation of novel 17-indazole androstene derivatives designed as CYP17 inhibitors.

Moreira VM, Vasaitis TS, Njar VC, Salvador JA. Moreira VM, et al. Among authors: njar vc. Steroids. 2007 Dec;72(14):939-48. doi: 10.1016/j.steroids.2007.08.004. Epub 2007 Aug 15. Steroids. 2007. PMID: 17884122

2

Synthesis of novel 21-trifluoropregnane steroids: inhibitors of 17 alpha-hydroxylase/17,20-lyase (17 alpha-lyase).

Njar VC, Klus GT, Johnson HH, Brodie AM. Njar VC, et al. Steroids. 1997 Jun;62(6):468-73. doi: 10.1016/s0039-128x(97)00016-0. Steroids. 1997. PMID: 9185294

3

Three dimensional pharmacophore modeling of human CYP17 inhibitors. Potential agents for prostate cancer therapy.

Clement OO, Freeman CM, Hartmann RW, Handratta VD, Vasaitis TS, Brodie AM, Njar VC. Clement OO, et al. Among authors: njar vc. J Med Chem. 2003 Jun 5;46(12):2345-51. doi: 10.1021/jm020576u. J Med Chem. 2003. PMID: 12773039

4

Novel C-17-heteroaryl steroidal CYP17 inhibitors/antiandrogens: synthesis, in vitro biological activity, pharmacokinetics, and antitumor activity in the LAPC4 human prostate cancer xenograft model.

Handratta VD, Vasaitis TS, Njar VC, Gediya LK, Kataria R, Chopra P, Newman D Jr, Farquhar R, Guo Z, Qiu Y, Brodie AM. Handratta VD, et al. Among authors: njar vc. J Med Chem. 2005 Apr 21;48(8):2972-84. doi: 10.1021/jm040202w. J Med Chem. 2005. PMID: 15828836

5

Retinoic acid metabolism blocking agents (RAMBAs) for treatment of cancer and dermatological diseases.

Njar VC, Gediya L, Purushottamachar P, Chopra P, Vasaitis TS, Khandelwal A, Mehta J, Huynh C, Belosay A, Patel J. Njar VC, et al. Bioorg Med Chem. 2006 Jul 1;14(13):4323-40. doi: 10.1016/j.bmc.2006.02.041. Epub 2006 Mar 10. Bioorg Med Chem. 2006. PMID: 16530416 Review.

6

First pharmacophore-based identification of androgen receptor down-regulating agents: discovery of potent anti-prostate cancer agents.

Purushottamachar P, Khandelwal A, Chopra P, Maheshwari N, Gediya LK, Vasaitis TS, Bruno RD, Clement OO, Njar VC. Purushottamachar P, et al. Among authors: njar vc. Bioorg Med Chem. 2007 May 15;15(10):3413-21. doi: 10.1016/j.bmc.2007.03.019. Epub 2007 Mar 13. Bioorg Med Chem. 2007. PMID: 17383188 Free PMC article.

7

Potent anti-prostate cancer agents derived from a novel androgen receptor down-regulating agent.

Purushottamachar P, Khandelwal A, Vasaitis TS, Bruno RD, Gediya LK, Njar VC. Purushottamachar P, et al. Among authors: njar vc. Bioorg Med Chem. 2008 Apr 1;16(7):3519-29. doi: 10.1016/j.bmc.2008.02.031. Epub 2008 Feb 14. Bioorg Med Chem. 2008. PMID: 18316193

8

CYP17 inhibitors for prostate cancer treatment--an update.

Moreira VM, Salvador JA, Vasaitis TS, Njar VC. Moreira VM, et al. Among authors: njar vc. Curr Med Chem. 2008;15(9):868-99. doi: 10.2174/092986708783955428. Curr Med Chem. 2008. PMID: 18473796 Review.

9

Synthesis of novel C17 steroidal carbamates. Studies on CYP17 action, androgen receptor binding and function, and prostate cancer cell growth.

Moreira VM, Vasaitis TS, Guo Z, Njar VC, Salvador JA. Moreira VM, et al. Among authors: njar vc. Steroids. 2008 Nov;73(12):1217-27. doi: 10.1016/j.steroids.2008.05.010. Epub 2008 Jun 6. Steroids. 2008. PMID: 18582482

10

Androgen receptor inactivation contributes to antitumor efficacy of 17{alpha}-hydroxylase/17,20-lyase inhibitor 3beta-hydroxy-17-(1H-benzimidazole-1-yl)androsta-5,16-diene in prostate cancer.

Vasaitis T, Belosay A, Schayowitz A, Khandelwal A, Chopra P, Gediya LK, Guo Z, Fang HB, Njar VC, Brodie AM. Vasaitis T, et al. Among authors: njar vc. Mol Cancer Ther. 2008 Aug;7(8):2348-57. doi: 10.1158/1535-7163.MCT-08-0230. Mol Cancer Ther. 2008. PMID: 18723482 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

98 results

Search Page